Subhan Z, Harrison C, Hindmarch I
Eur J Clin Pharmacol. 1986;29(6):709-12. doi: 10.1007/BF00615963.
The effects of alprazolam 0.5 mg and lorazepam 2 mg on cognitive and psychomotor skills were assessed in twelve normal volunteer subjects in a randomised, double-blind, crossover design. Single and multiple dose effects were monitored using a battery of tests comprising critical flicker fusion threshold (CFFT), choice reaction time (CRT), simulated car tracking, and subjective ratings of perceived sedation (LARS) and of sleep behaviour (LSEQ). Compared with placebo baseline scores, treatment with lorazepam 2 mg (both single and multiple doses) resulted in a widespread impairment of CRT, tracking accuracy, and CFFT. Single doses of alprazolam 0.5 mg reduced CFFT with respect to the placebo baseline. Single and multiple dose treatment with both drugs resulted in subjective reports of sedation, a reduction of sleep onset latency, and improved sleep quality. Only lorazepam 2 mg significantly disrupted the integrity of behaviour on waking from sleep. These results suggest important pharmacodynamic differences between the two drugs in the doses used.
采用随机、双盲、交叉设计，对12名正常志愿者进行了评估，以研究0.5毫克阿普唑仑和2毫克劳拉西泮对认知和精神运动技能的影响。使用一系列测试来监测单次和多次给药的效果，这些测试包括临界闪烁融合阈值（CFFT）、选择反应时间（CRT）、模拟汽车跟踪，以及对镇静感（LARS）和睡眠行为（LSEQ）的主观评分。与安慰剂基线分数相比，2毫克劳拉西泮治疗（单次和多次给药）均导致CRT、跟踪准确性和CFFT广泛受损。0.5毫克阿普唑仑单次给药使CFFT相对于安慰剂基线降低。两种药物的单次和多次给药治疗均导致了镇静的主观报告、入睡潜伏期缩短和睡眠质量改善。只有2毫克劳拉西泮显著扰乱了睡眠醒来时行为的完整性。这些结果表明，在所使用的剂量下，两种药物之间存在重要的药效学差异。
